Evidence map›Paper›PMID 36175999›Full record

ArticleJournal of nanobiotechnology2022

Boosting cisplatin chemotherapy by nanomotor-enhanced tumor penetration and DNA adducts formation.

Lihua Xu, Kaixiang Zhang, Xing Ma, Yingying Li, Yajie Jin, Chenglin Liang, Yong Wang, Wendi Duan, Hongling Zhang, Zhenzhong Zhang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Nanoenabled Intracellular Metal Ion Homeostasis Regulation for Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Lihua XuNational Center for International Research in Cell and Gene Therapy, Sino-British Research Center for Molecular Oncology, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Kaixiang ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Xing MaSchool of Materials Science and Engineering & Flexible Printed Electronic Technology Center, Harbin Institute of Technology (Shenzhen), Shenzhen, 518055, China.
Yingying LiSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Yajie JinSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Chenglin LiangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Yong WangSchool of Materials Science and Engineering & Flexible Printed Electronic Technology Center, Harbin Institute of Technology (Shenzhen), Shenzhen, 518055, China.
Wendi DuanSchool of Materials Science and Engineering & Flexible Printed Electronic Technology Center, Harbin Institute of Technology (Shenzhen), Shenzhen, 518055, China.
Hongling ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Zhenzhong ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Jinjin ShiSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Junjie LiuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Yunlong WangHenan Bioengineering Research Center, Zhengzhou, 450000, Henan, China. biowyl@126.com.
Wentao LiDepartment of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, Henan, China. lwt9225@163.com.
Zhengzhou University · CNHarbin Institute of Technology · CNHenan Provincial People's Hospital · CN

Funding

National Natural Science Foundation of China Nos. 81874304, 82172762, 31900991, 82073395Shenzhen Science and Technology Program KQTD20170809110344233
6 · The paper itself

Abstract

Despite many nano-based strategies devoted to delivering cisplatin for tumor therapy, its clinical benefits are compromised by poor tissue penetration and limited DNA adducts formation of the drug. Herein, a cisplatin loading nanomotor based janus structured Ag-polymer is developed for cisplatin delivery of deeper tissue and increased DNA adducts formation. The nanomotor displayed a self-propelled tumor penetration fueled by hydrogen peroxide (H

Indexed as

Antineoplastic AgentsMetal NanoparticlesNeoplasmsCisplatinDNADNA AdductsHumansHydrogen PeroxideOxygenPolymersSilverAntineoplastic AgentsCisplatinDNADNA AdductsHydrogen PeroxideOxygenPolymersSilverCisplatin chemotherapyDNA adductIon regulationNanomotorTumor penetration

Identifiers

PMID36175999
PMCPMC9523964
OpenAlexW4297963077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.